Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tetratherix Limited ( (AU:TTX) ) has provided an announcement.
Tetratherix has cleared a key safety milestone in the development of its TetraDerm surgical wound product, with the second cohort of its clinical trial completing six-week follow-up and a second safety review without any procedural or technical adverse events. The trial is now moving into a third and final cohort that will predominantly comprise patients undergoing body contouring procedures after significant weight loss, positioning TetraDerm in a rapidly expanding reconstructive surgery market driven by uptake of obesity and weight-loss treatments; management says this phase marks the final validation step before commercialisation and could establish TetraDerm as a high-margin, scalable solution for large, complex surgical sites in a multi‑billion‑dollar segment.
The most recent analyst rating on (AU:TTX) stock is a Buy with a A$5.76 price target. To see the full list of analyst forecasts on Tetratherix Limited stock, see the AU:TTX Stock Forecast page.
More about Tetratherix Limited
Tetratherix Limited (ASX: TTX) is a medical technology developer focused on novel clinical products built on a patented biomaterial polymer platform. Its lead product, TetraDerm, is designed for surgical site management, aiming to prevent scar formation and improve wound healing outcomes, with a particular focus on high-growth segments such as plastic and reconstructive surgery linked to major weight loss and body contouring procedures.
Average Trading Volume: 9,567
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$163.5M
See more insights into TTX stock on TipRanks’ Stock Analysis page.